Skip to main content
SpringerLink
Log in

Prevention and Management of Gout

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Gout is a common disease with a worldwide distribution. The major risk factor for the development of gout is sustained asymptomatic hyperuricaemia. Although pharmacological therapy of asymptomatic hyperuricaemia is not recommended, primary prevention of gout can be achieved through lifestyle changes including weight loss, restricting protein and calorie intake, limiting alcohol consumption, avoiding the use of diuretics in the treatment of hypertension, and avoiding occupational exposure to lead.

The arthritis of gout can be readily managed with the use of nonsteroidal anti-inflammatory drugs (NSAIDs); systemic steroids or corticotrophin (adrenocorticotrophic hormone; ACTH) should be used in patients with contraindications to NSAIDs, or who are intolerant of them. Because of potential toxicity, colchicine should not be used to treat acute gout, but should be used in low dosage (0.6 to 1.2 mg/day) for prophylaxis of recurrent attacks of gout.

The other cornerstone of prevention of recurrent gouty attacks is control of hyperuricaemia, which can be effectively accomplished with antihyperuricaemic therapy. The choice of agents, either uricosuric drugs or xanthine oxidase inhibitors, is based on the level of urinary uric acid excretion, renal function, age of patient, history of renal calculi and presence of tophi. Treatment and prevention of gout are exceedingly effective and patients can usually be managed by their primary care physician.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham study. Journal of Clinical Epidemiology 41: 237–242, 1988

    Article  PubMed  CAS  Google Scholar 

  • Abramson SB. Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs. Current Opinion in Rheumatology 4: 295–300, 1992

    Article  PubMed  CAS  Google Scholar 

  • Ali M, McDonald WD. Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. Journal of Laboratory and Clinical Medicine 89: 868–875, 1977

    PubMed  CAS  Google Scholar 

  • Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of gout. Arthritis and Rheumatism 31: 803–805, 1988

    Article  PubMed  CAS  Google Scholar 

  • Boss GR, Seegmiller JE. Hyperuricemia and gout: classification, complications and management. New England Journal of Medicine 300: 1459–1468, 1979

    Article  PubMed  CAS  Google Scholar 

  • Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. American Journal of Medicine 82: 421–426, 1987

    Article  PubMed  CAS  Google Scholar 

  • Dawson DA, Adams PF. Current estimates from the National Health Interview Survey, United States, 1986. Vital and Health Statistics. Series 10, No. 164. DHHS Pub. No. (PHS) 87-1592. Public Health Service. Washington, U.S. Government Printing Office, Oct, 1987

  • Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Seminars in Arthritis and Rheumatism 19: 329–336, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. American Journal of Medicine 42: 27–37, 1967

    Article  PubMed  CAS  Google Scholar 

  • Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. American Journal of Medicine 76: 47–56, 1984

    Article  PubMed  CAS  Google Scholar 

  • Hochberg MC. Opportunities for the primary and secondary prevention of gout. Mediguide Inflammatory Diseases 10: 1–5, 1991

    Google Scholar 

  • Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, et al. Colchicine myopathy and neuropathy. New England Journal of Medicine 316: 1562–1568, 1987

    Article  PubMed  CAS  Google Scholar 

  • Liang MH, Fries JF. Asymptomatic hyperuricemia: the case for conservative management. Annals of Internal Medicine 88: 666–670, 1978

    PubMed  CAS  Google Scholar 

  • Malawista SE. The action of colchicine in acute gouty arthritis. Arthritis and Rheumatism 18: 835–846, 1975

    Article  PubMed  CAS  Google Scholar 

  • Masternard A, Giudicelli CP. Ten years experience with benz-bromarone in the management of gout and hyperuricemia. South African Medical Journal 59: 701–706, 1981

    Google Scholar 

  • Moreland LW, Ball GV. Colchicine and gout. Arthritis and Rheumatism 34: 782–786, 1991

    Article  PubMed  CAS  Google Scholar 

  • Nicholls A, Scott JT. Effect of weight loss on plasma and urinary levels of uric acid. Lancet 2: 1223–1224, 1972

    Article  PubMed  CAS  Google Scholar 

  • Richter BS. A case-control study of lead exposure and other risk factors for gouty arthritis. PhD Thesis, The Johns Hopkins University, Baltimore, 1987

  • Roberts WM, Liang MH, Stern SH. Colchicine in acute gout. Journal of the American Medical Association 257: 1920–1921, 1987

    Article  PubMed  CAS  Google Scholar 

  • Roubenoff R, Klag MJ, Mead LA, Liang K-Y, Seidler AJ, et al. Incidence and risk factors for gout in white men. Journal of the American Medical Association 266: 3004–3007, 1991

    Article  PubMed  CAS  Google Scholar 

  • Silman AJ, Hochberg MC. Epidemiology of the Rheumatic Diseases. Oxford University Press, Oxford, 1993

    Google Scholar 

  • Simkin PA. Management of gout. Annals of Internal Medicine 90: 812–816, 1979

    PubMed  CAS  Google Scholar 

  • Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis and Rheumatism 29: 82–87, 1986

    Article  PubMed  CAS  Google Scholar 

  • Sterling LP. The clinical management of gout. American Pharmacy NS31: 368–374, 1991

    Google Scholar 

  • Talbott J, Yu TF. Gout and Uric Acid Metabolism, pp. (1–25), Stratton Intercontinental Medical Book Corp., New York, 1976

  • Wallace SL, Bernstein D, Diamond H. Diagnostic value of the colchicine therapeutic trial. Journal of the American Medical Association 199: 525–528, 1967

    Article  PubMed  CAS  Google Scholar 

  • Wallace SL, Robinson H, Masi AT, Decker JL, McCarthy DJ, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis and Rheumatism 20: 895–900, 1977

    Article  PubMed  CAS  Google Scholar 

  • Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine — guidelines for use. Journal of Rheumatology 15: 495–499, 1988a

    PubMed  CAS  Google Scholar 

  • Wallace SL, Singer JZ. Therapy in gout. Rheumatic Diseases Clinics of North America 14: 441–457, 1988b

    PubMed  CAS  Google Scholar 

  • Wallace SL, Singer JZ, Duncan DJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. Journal of Rheumatology 18: 264–269, 1991

    PubMed  CAS  Google Scholar 

  • Weiner IM. Inhibitors of tubular transport of organic compounds. In Gilman et al. (Eds) Goodman and Gilman’s textbook of pharmacology, 8th ed., pp. 743–748, Pergamon Press, London, 1990

    Google Scholar 

  • Wolfe F. Gout and hyperuricemia. American Family Physician 43: 2131–2150, 1991

    Google Scholar 

  • Yu TF, Gutman AB. Efficiency of colchicine prophylaxis in gout. Annals of Internal Medicine 55: 179–192, 1961

    PubMed  CAS  Google Scholar 

  • Yu TF. The efficacy of colchicine prophylaxis in articular gout: a reappraisal after 20 years. Seminars in Arthritis and Rheumatism 12: 256–264, 1982

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA

    Vicki L. Star &  Marc C. Hochberg

  2. Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA

    Marc C. Hochberg

Authors
  1. Vicki L. Star
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc C. Hochberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Star, V.L., Hochberg, M.C. Prevention and Management of Gout. Drugs 45, 212–222 (1993). https://doi.org/10.2165/00003495-199345020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199345020-00004

Keywords

Search

Navigation